Market Overview:
The global market for Mitogen Activated Protein Kinase 9 is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and growing investments in R&D. The global market for Mitogen Activated Protein Kinase 9 is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ER-358063, SR-3306, TT-301 and others. On the basis of application, it is divided into clinic settings and hospital settings.
Product Definition:
Mitogen Activated Protein Kinase 9 (MAPK9), also known as c-Jun N-terminal kinases (JNKs), are a family of proteins that are involved in cellular signaling. MAPK9 is activated by mitogens, including cytokines and growth factors, and is responsible for the activation of transcription factors such as c-jun. The importance of MAPK9 lies in its role in regulating apoptosis, or programmed cell death, as well as mediating the effects of stress on cells.
ER-358063:
ER-358063 is a novel, potent and selective inhibitor of MEK9 (mitogen-activated protein kinase 9). It has been shown to have an IC50 value of 0.41 uM in vitro and 0.15 uM in vivo. The compound exhibits high oral bioavailability as it is formulated as a racemic mixture with each enantiomer having approximately 50% of the pharmacological potency.
SR-3306:
SR-3306 is a selective androgen receptor modulator (SAROM) developed by Sarepta. It's chemical structure is very similar to that of testosterone but it has much lower potency than the male sex hormone. SR-3306 has been found to have an effect on muscle strength, body composition, bone metabolism and also affects some cardiovascular parameters such as blood pressure & heart rate.
Application Insights:
The other applications segment includes research and diagnostic centers. The application of GMAK in the aforementioned regions is expected to witness significant growth over the forecast period owing to increasing prevalence of cancer which kinase 9 plays a major role in the treatment.
In addition, growing R&D activities pertaining to oncology by various companies including Pfizer, Inc., Merck KGaA, Roche Products Limited and sanofi Aventis is likely to boost market growth during the study period. In addition, new product launches coupled with strategic collaborations are anticipated to bolster market penetration over the coming years. For instance, Pfizer collaborated with Amgen regarding development of pan-cancer immunotherapies based on T cell recognition for advanced therapy that targets non-small cell lung cancer (NSCLC). This collaboration was followed by another one between Merck & Co.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, high adoption rate for advanced diagnostics and therapeutics, and favorable reimbursement policies are some factors attributing to its largest share. In addition, increasing prevalence of cancer is also expected to drive the regional market over the forecast period. For instance, according to data published by American Cancer Society in 2018, approximately 1 million new cases were estimated to be diagnosed in U.S., with about 600 thousand deaths due to it annually.
Asia Pacific is expected witness lucrative growth during the forecast period owing to rising healthcare expenditure levels coupled with growing awareness regarding early diagnosis among patients as well as physicians which ultimately leads towards improved treatment rates thus resulting into higher revenue generation from Mitogen-Activated Protein Kinase 9 (MAPK9) drugs sales within this region over time compared with other regions globally 8).
Growth Factors:
- Increasing prevalence of cancer and other diseases that can be treated with MAPK9 inhibitors
- Growing demand for targeted therapies to treat cancer and other diseases
- increasing investment in research and development of new MAPK9 inhibitors
- rising number of clinical trials evaluating the safety and efficacy of MAPK9 inhibitors
- expanding use of MAPK9 inhibitors in combination therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Mitogen Activated Protein Kinase 9 Market Research Report
By Type
ER-358063, SR-3306, TT-301, Others
By Application
Clinic, Hospital, Others
By Companies
Eisai Co Ltd, OPKO Health Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Mitogen Activated Protein Kinase 9 Market Report Segments:
The global Mitogen Activated Protein Kinase 9 market is segmented on the basis of:
Types
ER-358063, SR-3306, TT-301, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eisai Co Ltd
- OPKO Health Inc
Highlights of The Mitogen Activated Protein Kinase 9 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ER-358063
- SR-3306
- TT-301
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mitogen Activated Protein Kinase 9 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mitogen-activated protein kinase 9 (MAPK9) is a serine/threonine kinase that is activated by mitogens, including stress hormones and growth factors. MAPK9 plays a role in the regulation of cell proliferation, differentiation, and survival.
Some of the major companies in the mitogen activated protein kinase 9 market are Eisai Co Ltd, OPKO Health Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mitogen Activated Protein Kinase 9 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mitogen Activated Protein Kinase 9 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mitogen Activated Protein Kinase 9 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mitogen Activated Protein Kinase 9 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mitogen Activated Protein Kinase 9 Market Size & Forecast, 2020-2028
4.5.1 Mitogen Activated Protein Kinase 9 Market Size and Y-o-Y Growth
4.5.2 Mitogen Activated Protein Kinase 9 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ER-358063
5.2.2 SR-3306
5.2.3 TT-301
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mitogen Activated Protein Kinase 9 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mitogen Activated Protein Kinase 9 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ER-358063
9.6.2 SR-3306
9.6.3 TT-301
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ER-358063
10.6.2 SR-3306
10.6.3 TT-301
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ER-358063
11.6.2 SR-3306
11.6.3 TT-301
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ER-358063
12.6.2 SR-3306
12.6.3 TT-301
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ER-358063
13.6.2 SR-3306
13.6.3 TT-301
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mitogen Activated Protein Kinase 9 Market: Competitive Dashboard
14.2 Global Mitogen Activated Protein Kinase 9 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eisai Co Ltd
14.3.2 OPKO Health Inc
